Diffuse Large B-Cell Lymphoma DLBCL, an aggressive cancer, accounts for about 30% of
all lymphomas. Empirical combination chemotherapy cures about 65% of patients initially …

Diffuse large B cell lymphoma (DLBCL), the most common type of Non‐Hodgkin lymphoma
(NHL), comprises a heterogeneous group of diseases with different biology, clinical …

PURPOSE Diffuse large B-cell lymphoma (DLBCL) presents as a limited-stage disease in
25% to 30% of patients, with better overall survival (OS) than that for advanced-stage …

The benefit of radiotherapy (RT) after chemotherapy in limited-stage diffuse large B-cell
lymphoma (DLBCL) remains controversial. We conducted a randomized trial in patients with …

Five-year survival has increased for many hematologic malignancies in the 21st century.
However, whether this has translated into greater long-term survival is unknown. Here, we …

Diffuse large B-cell lymphoma (DLBCL) represents a curable disease with a 60–70%
chance of cure with current R-CHOP chemoimmunotherapy. However, 30–40% of patients …

Most patients with diffuse large B‐cell lymphoma (DLBCL) are diagnosed at age 60 years or
older. Challenges to effective therapy among older individuals include unfavorable biologic …

Diffuse large B-cell lymphoma (DLBCL), the most common lymphoma subtype, is localized
in 25% to 30% of patients. Prognosis in patients with limited-stage DLBCL (LS-DLBCL) is …

Diffuse large B-cell lymphoma, the most common subtype of non-Hodgkin lymphoma,
comprises a heterogenous group of morphologically, genetically, and clinically distinct …

Abstract Treatment with rituximab plus a regimen of cyclophosphamide, doxorubicin,
vincristine and prednisolone (CHOP) for patients with diffuse large B-cell lymphoma …